Fig. 2. Durability comparison between too STRs. (A) Overall durability at week 96 was not significantly different between D/A/L and E/T/E. (B) However, worse durability related to AEDC was observed in D/A/L group at week 96 and throughout the study period.

AEDC = adverse event related discontinuation, D/A/L = dolutegravir/abacavir/lamivudine, E/T/E = elvitegravir/cobicistat/tenofovir disoproxil fumarate/emtricitabine and elvitegravir/tenofovir alafenamide/emtricitabine.